H.R.6640 - Medicare Advantage COVID Treatment Act116th Congress (2019-2020) |
|Sponsor:||Rep. Mucarsel-Powell, Debbie [D-FL-26] (Introduced 04/28/2020)|
|Committees:||House - Ways and Means; Energy and Commerce|
|Latest Action:||House - 04/28/2020 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.6640 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (04/28/2020)
Medicare Advantage COVID Treatment Act
This bill requires Medicare Advantage (MA) plans to cover specified treatment services relating to COVID-19 (i.e., coronavirus disease 2019) without cost-sharing during the public health emergency declared on January 31, 2020. The CMS must reimburse MA plans for cost-sharing amounts that would otherwise have been received, in accordance with a specified timeline.
MA plans are also prohibited from instituting prior authorization or other utilization management requirements with respect to coverage of specified critical treatment services (e.g., ventilator services and intensive care unit services).